Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Doxorubicin and Trabectedin in Uterine Leiomyosarcoma
NCT07076186Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Targeted Liposomes, Nucleic Acid-Directed Small Molecules, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, trabectedin in uterine leiomyosarcoma (uLMS), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2025; status: recruiting.
02
Drugs
pegylated liposomal doxorubicintrabectedin
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT07076186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076186.